Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

247
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
247
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

989
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
989
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nasal-Temporal Asymmetry in Retinopathy of Prematurity as a Source of Diagnostic Bias and Error.

Ophthalmology. Retina·2026
Same author

Monitoring outcomes of the first human whole eye allotransplant.

Documenta ophthalmologica. Advances in ophthalmology·2026
Same author

Logistical, Ethical, and Technical Considerations in the World's First Face and Whole Eye Transplantation.

Plastic and reconstructive surgery·2025
Same author

Response to Letter to the Editor regarding: "10-year Follow-Up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Anti-VEGF Injections".

Retina (Philadelphia, Pa.)·2025
Same author

Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment.

Eye (London, England)·2025
Same author

Panretinal Congenital Hypertrophy of the RPE in an 8-Year-Old Girl with an X-Linked STAG2 Mutation.

Journal of clinical medicine·2025
Same journal

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Ophthalmic Implications of Ehlers-Danlos Syndrome.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Diagnostic Value of Pupil Involvement and Yield of Vascular Imaging in Isolated Third Cranial Nerve Palsy: A 10-Year Retrospective Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Short-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Chemical and Thermal Ocular Burns in Children: A Retrospective Single-Center Study of Etiology, Clinical Characteristics, and Outcomes.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same journal

Two-Year Follow-Up of the MINI WELL Non-Diffractive Extended Depth-of-Focus Intraocular Lens: A Retrospective Observational Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Current perspectives on ranibizumab.

Vaidehi S Dedania1, Sophie J Bakri2

  • 1Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA.

Clinical Ophthalmology (Auckland, N.Z.)
|April 8, 2015
PubMed
Summary
This summary is machine-generated.

Intravitreal ranibizumab injections significantly improve vision for patients with age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME). This safe and effective treatment offers long-term benefits with manageable adverse events.

Keywords:
age-related macular degenerationbranch retinal vein occlusioncentral retinal vein occlusiondiabetic macular edemaintravitrealmacular edema

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K

Related Experiment Videos

Last Updated: Apr 15, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Pharmacological Treatments

Background:

  • Review of Phase III studies on intravitreal ranibizumab.
  • Focus on neovascular age-related macular degeneration (AMD), macular edema (ME) from retinal vein occlusion (RVO), and diabetic ME (DME).

Purpose of the Study:

  • Summarize efficacy and safety data of intravitreal ranibizumab.
  • Evaluate treatment outcomes in major ophthalmic conditions.

Main Methods:

  • Analysis of 12 major Phase III clinical trials.
  • Comparison of intravitreal ranibizumab treatment versus control groups (no treatment or grid laser).

Main Results:

  • Significant vision improvement observed in treated patients across all studied conditions.
  • Low incidence of ocular and nonocular adverse events reported.
  • Intravitreal ranibizumab demonstrated superior outcomes compared to control interventions.

Conclusions:

  • Intravitreal ranibizumab is a highly effective and safe therapy for neovascular AMD, ME from RVO, and DME.
  • Long-term treatment is generally required, with potential for decreased treatment frequency over time to maintain visual outcomes.